CBL and Alzheimer disease: These data altogether indicate that a subset of AD patients (12/45, ~27% of this series) present with microglial clones carrying one or several oncogenic variants that activate the RTK/MAPK pathway, and are characterized by recurrent oncogenic variants in CBL and RIT1.